These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1904 related items for PubMed ID: 24820015

  • 1. Relationship between β-Secretase, inflammation and core cerebrospinal fluid biomarkers for Alzheimer's disease.
    Alcolea D, Carmona-Iragui M, Suárez-Calvet M, Sánchez-Saudinós MB, Sala I, Antón-Aguirre S, Blesa R, Clarimón J, Fortea J, Lleó A.
    J Alzheimers Dis; 2014; 42(1):157-67. PubMed ID: 24820015
    [Abstract] [Full Text] [Related]

  • 2. Amyloid precursor protein metabolism and inflammation markers in preclinical Alzheimer disease.
    Alcolea D, Martínez-Lage P, Sánchez-Juan P, Olazarán J, Antúnez C, Izagirre A, Ecay-Torres M, Estanga A, Clerigué M, Guisasola MC, Sánchez Ruiz D, Marín Muñoz J, Calero M, Blesa R, Clarimón J, Carmona-Iragui M, Morenas-Rodríguez E, Rodríguez-Rodríguez E, Vázquez Higuera JL, Fortea J, Lleó A.
    Neurology; 2015 Aug 18; 85(7):626-33. PubMed ID: 26180139
    [Abstract] [Full Text] [Related]

  • 3. Cerebrospinal fluid level of YKL-40 protein in preclinical and prodromal Alzheimer's disease.
    Antonell A, Mansilla A, Rami L, Lladó A, Iranzo A, Olives J, Balasa M, Sánchez-Valle R, Molinuevo JL.
    J Alzheimers Dis; 2014 Aug 18; 42(3):901-8. PubMed ID: 25024322
    [Abstract] [Full Text] [Related]

  • 4. Decreased sAβPPβ, Aβ38, and Aβ40 cerebrospinal fluid levels in frontotemporal dementia.
    Gabelle A, Roche S, Gény C, Bennys K, Labauge P, Tholance Y, Quadrio I, Tiers L, Gor B, Boulanghien J, Chaulet C, Vighetto A, Croisile B, Krolak-Salmon P, Perret-Liaudet A, Touchon J, Lehmann S.
    J Alzheimers Dis; 2011 Aug 18; 26(3):553-63. PubMed ID: 21709372
    [Abstract] [Full Text] [Related]

  • 5. Relationship between cortical thickness and cerebrospinal fluid YKL-40 in predementia stages of Alzheimer's disease.
    Alcolea D, Vilaplana E, Pegueroles J, Montal V, Sánchez-Juan P, González-Suárez A, Pozueta A, Rodríguez-Rodríguez E, Bartrés-Faz D, Vidal-Piñeiro D, González-Ortiz S, Medrano S, Carmona-Iragui M, Sánchez-Saudinós M, Sala I, Anton-Aguirre S, Sampedro F, Morenas-Rodríguez E, Clarimón J, Blesa R, Lleó A, Fortea J.
    Neurobiol Aging; 2015 Jun 18; 36(6):2018-23. PubMed ID: 25865441
    [Abstract] [Full Text] [Related]

  • 6. Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohort.
    Seeburger JL, Holder DJ, Combrinck M, Joachim C, Laterza O, Tanen M, Dallob A, Chappell D, Snyder K, Flynn M, Simon A, Modur V, Potter WZ, Wilcock G, Savage MJ, Smith AD.
    J Alzheimers Dis; 2015 Jun 18; 44(2):525-39. PubMed ID: 25391385
    [Abstract] [Full Text] [Related]

  • 7. Soluble BACE-1 Activity and sAβPPβ Concentrations in Alzheimer's Disease and Age-Matched Healthy Control Cerebrospinal Fluid from the Alzheimer's Disease Neuroimaging Initiative-1 Baseline Cohort.
    Savage MJ, Holder DJ, Wu G, Kaplow J, Siuciak JA, Potter WZ, Foundation for National Institutes of Health (FNIH) Biomarkers Consortium CSF Proteomics Project Team for Alzheimer's Disease Neuroimaging Initiative.
    J Alzheimers Dis; 2015 Jun 18; 46(2):431-40. PubMed ID: 25790831
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Interrelations between CSF soluble AβPPβ, amyloid-β 1-42, SORL1, and tau levels in Alzheimer's disease.
    Alexopoulos P, Guo LH, Tsolakidou A, Kratzer M, Grimmer T, Westerteicher C, Jiang M, Bujo H, Diehl-Schmid J, Kurz A, Perneczky R.
    J Alzheimers Dis; 2012 Jun 18; 28(3):543-52. PubMed ID: 22045485
    [Abstract] [Full Text] [Related]

  • 10. Neurogranin and YKL-40: independent markers of synaptic degeneration and neuroinflammation in Alzheimer's disease.
    Hellwig K, Kvartsberg H, Portelius E, Andreasson U, Oberstein TJ, Lewczuk P, Blennow K, Kornhuber J, Maler JM, Zetterberg H, Spitzer P.
    Alzheimers Res Ther; 2015 Dec 24; 7():74. PubMed ID: 26698298
    [Abstract] [Full Text] [Related]

  • 11. Alzheimer's disease biomarker-guided diagnostic workflow using the added value of six combined cerebrospinal fluid candidates: Aβ1-42, total-tau, phosphorylated-tau, NFL, neurogranin, and YKL-40.
    Hampel H, Toschi N, Baldacci F, Zetterberg H, Blennow K, Kilimann I, Teipel SJ, Cavedo E, Melo Dos Santos A, Epelbaum S, Lamari F, Genthon R, Dubois B, Floris R, Garaci F, Lista S, Alzheimer Precision Medicine Initiative (APMI).
    Alzheimers Dement; 2018 Apr 24; 14(4):492-501. PubMed ID: 29328927
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. The Inflammatory Marker YKL-40 Is Elevated in Cerebrospinal Fluid from Patients with Alzheimer's but Not Parkinson's Disease or Dementia with Lewy Bodies.
    Wennström M, Surova Y, Hall S, Nilsson C, Minthon L, Hansson O, Nielsen HM.
    PLoS One; 2015 Apr 24; 10(8):e0135458. PubMed ID: 26270969
    [Abstract] [Full Text] [Related]

  • 17. Cerebrospinal Fluid YKL-40 and Chitotriosidase Levels in Frontotemporal Dementia Vary by Clinical, Genetic and Pathological Subtype.
    Woollacott IOC, Nicholas JM, Heller C, Foiani MS, Moore KM, Russell LL, Paterson RW, Keshavan A, Schott JM, Warren JD, Heslegrave A, Zetterberg H, Rohrer JD.
    Dement Geriatr Cogn Disord; 2020 Apr 24; 49(1):56-76. PubMed ID: 32344399
    [Abstract] [Full Text] [Related]

  • 18. Two-level diagnostic classification using cerebrospinal fluid YKL-40 in Alzheimer's disease.
    Baldacci F, Toschi N, Lista S, Zetterberg H, Blennow K, Kilimann I, Teipel S, Cavedo E, Dos Santos AM, Epelbaum S, Lamari F, Dubois B, Floris R, Garaci F, Bonuccelli U, Hampel H.
    Alzheimers Dement; 2017 Sep 24; 13(9):993-1003. PubMed ID: 28263742
    [Abstract] [Full Text] [Related]

  • 19. Cerebrospinal Fluid Markers of Alzheimer's Disease Pathology and Microglial Activation are Associated with Altered White Matter Microstructure in Asymptomatic Adults at Risk for Alzheimer's Disease.
    Melah KE, Lu SY, Hoscheidt SM, Alexander AL, Adluru N, Destiche DJ, Carlsson CM, Zetterberg H, Blennow K, Okonkwo OC, Gleason CE, Dowling NM, Bratzke LC, Rowley HA, Sager MA, Asthana S, Johnson SC, Bendlin BB.
    J Alzheimers Dis; 2016 Sep 24; 50(3):873-86. PubMed ID: 26836182
    [Abstract] [Full Text] [Related]

  • 20. YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer's disease.
    Craig-Schapiro R, Perrin RJ, Roe CM, Xiong C, Carter D, Cairns NJ, Mintun MA, Peskind ER, Li G, Galasko DR, Clark CM, Quinn JF, D'Angelo G, Malone JP, Townsend RR, Morris JC, Fagan AM, Holtzman DM.
    Biol Psychiatry; 2010 Nov 15; 68(10):903-12. PubMed ID: 21035623
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 96.